Publications by authors named "R C Shnier"
Background: In active surveillance there is significant interest in whether imaging modalities such as multiparametric magnetic resonance imaging (mpMRI) or Gallium prostate-specific membrane antigen positron emission tomography/computerized tomography (Ga-PSMA-PET/CT) can improve the detection of progression to clinically significant prostate cancer (csPCa) and thus reduce the frequency of prostate biopsies and associated morbidity. Recent studies have demonstrated the value of mpMRI in active surveillance; however, mpMRI does miss a proportion of disease progression and thus alone cannot replace biopsy. To date, prostate-specific membrane antigen positron emission tomography (PSMA-PET) has shown additive value to mpMRI in its ability to detect prostate cancer (PCa) in the primary diagnostic setting.
View Article and Find Full Text PDFObjectives: To evaluate the safety, and short to mid-term oncological and quality-of-life (QoL) outcomes of focal irreversible electroporation (IRE) for radio-recurrent prostate cancer (PCa) at a median follow-up of 4 years.
Patients And Methods: This was a single-centre series of men with biopsy-proven radio-recurrent PCa treated with IRE between December 2013 and February 2022, with a minimum follow-up of 6 months. Follow-up included magnetic resonance imaging at 6 months, and standard transperineal saturation template biopsies at 12 months.
Article Synopsis
- The study investigates the safety and effectiveness of irreversible electroporation (IRE) as a treatment for patients with localized prostate cancer that recurred after radiation therapy.
- It included 37 men with recurrent prostate cancer, and the results indicated that IRE led to a high rate of local disease control (78%) while maintaining a majority of patients' continence (93%).
- Adverse effects were minimal, with only a small number reporting significant issues, though some experienced a decline in erectile function after treatment, highlighting IRE as a promising option for salvage therapy.
Article Synopsis
- The study aims to assess the long-term outcomes of using focal irreversible electroporation (IRE) for treating localized clinically significant prostate cancer over a median follow-up of 5 years (up to 10 years).
- Out of 229 patients treated between February 2013 and August 2021, the failure-free survival rates were high at 91% at 3 years, 84% at 5 years, and 69% at 8 years, with minimal cases of metastasis and no overall mortality.
- Functional outcomes showed high rates of urinary continence preservation (98%) but a slight decline in erectile function (from 71% to 58%), indicating that IRE is a viable option for localized prostate cancer